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ABSTRACT 
Proteomic scale effect of HSP90 inhibition with 17-AAG and Radicicol 
 Heat Shock Protein 90 is a molecular chaperone with a function of folding the 
proteins involved in cell signaling, such as transcription factors and protein 
kinases. Under stressful conditions, HSP90 stabilizes its client proteins and 
provides protection to the cell against cellular stressors such as in cancer cells. 
Through mutations, cancer cells become dependent on oncogenic pathways. Then 
the most malignant tumor cells are selected for cloning. As this malignant process 
proceeds, there is a need for the up-regulation of HSP90. The dependency of the 
cancer cells on HSP90 increases to a great extent as HSP90 protects the over-
expressed and unstable oncogenic proteins. Therefore, it makes sense to say that if 
we inhibit HSP90 it would be beneficial for all types of cancer. The promising 
anti-tumor activity of 17-allylamino-17demethoxygeldanamycin (17AAG) and 
Radicicol results from the inhibition of HSP90.  Proteomic analysis was done to 
study the effect of HSP90 inhibitors after 24 hours of drug treatment. Lung 
epithelial cancer cells were given a treatment of 60nM of 17AAG and 600nM of 
Radicicol. Mass Spectrometry (LC-MS/MS) and Western Blotting were used to 
analyze the drug treated and untreated samples.  The drugs bind at the ATP 
pocket of HSP90 and disrupt the HSP90 complex that stabilizes the client 
proteins. An increase in the expression of HSP90 and HSP70 is observed. This 
might mean that the complex that assists in folding of the client proteins is 
disrupted which can be beneficial, as the cancer cells would be deprived of the 
oncogenic proteins that they rely on. Furthermore, the results from drug treated 
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A549 cells were compared to Mesenchymal Stem Cells (MSC’s). This can help in 
studying the effect of drugs on a wider variety of cells. MSC’s are 
undifferentiated cells; which can differentiate into various cell types, example 
adipocytes, chondrocytes and cardiomyocytes. Giving the drug treatment to 
MSC’s would help us in understanding the effect of the drugs on the cells and 
whether the cells were harmed or not. This information can prove to be beneficial 
before testing the drugs in people. Hence treating MSC with 17-AAG and 
Radicicol would help in testing the safety and quality of the drugs. 
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Chapter 1. INTRODUCTON 
 
1.1 Statement of the problem 
Cancer is a disease of cellular dysfunction involving a range of biological 
activities that promote unregulated proliferation of cells. Therapeutic design for 
treatment of cancer has become finely tuned toward single aberrant molecular 
pathways. However the resulting drugs have in most cases (with the exception of 
Gleevec and retinoic acid) achieved only limited efficacy (Smith-Jones et al., 
2004). The incomplete knowledge of the function of the individual signaling 
proteins and the difficulty in determining the pharmacodynamic effects of their 
inhibitors in vivo are still considered to be a big problem. Thus far, the effect of 
an inhibitor on its target in the tumor can be determined by using proteomic 
techniques to study its effect in vitro. Heat shock protein90 (HSP90) accounts for 
nearly 1% of total protein of the cell and is responsible for folding of a large 
number of proteins in combination with various co-chaperones, immunophilins 
and partner proteins (Garnier et al., 2002). Under stress conditions, HSP90 
stabilizes its client proteins and provides protection to the cells against cellular 
stressors example Src family kinases, Raf, receptor tyrosine kinases such as erB1 
and human epidermal growth factor receptor 2 (HER2), mutant p53, telomerase, 
the steroid hormone receptors and mesenchymal-epithelial transition (MET) 
factor (kinase) in cancer cells (Mahalingam, et al., 2009). Disruption of HSP90 
leads to client protein degradation and often cell death. It has been found that 
HSP90 is over expressed in cancer cells; hence the inhibition of HSP90 may have 
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cancer selectivity (Holzbeierlein, Windsperger, & Vielhauer, 2010). Two N-
terminal inhibitors of HSP90, 17 allylamino- 17 demethoxygeldanamycin 
(17AAG) and Radicicol have been studied in a number of clinical trials. Previous 
work has shown the promising antitumor activity of 17AAG by inhibiting HSP90. 
Gene expression microarray analysis and proteomic profiling were used to 
compare the effects of treatment with 17AAG and Radicicol and an inactive 
analogue on A2780 human ovarian cancer cells. The results indicated an 
increased expression of various proteins like HSP72, HSC70, HSP27, HSP47 and 
HSP90β at the mRNA level in cells treated with 17AAG (Maloney et al., 2007). 
Although HSP90 is a potential target for cancer therapy due to its crucial role in 
“guarding the proteome”, there are challenges to be overcome in developing 
HSP90 inhibitors as anticancer drugs. It is hard to define the appropriate way in 
which to deploy the HSP90 inhibitors in the treatment of cancer (L. Whitesell & 
S. L. Lindquist, 2005). Previous work has shown the effects of HSP90 inhibition 
on HSP90 client proteins in various tumor cell types in vitro. There is a need to 
study the potential effects of HSP90 inhibition in vivo. Also there is a need to 
study the effects of HSP90 inhibition on the tumor evolution and progression. 
1.2 Hypothesis  
The primary hypothesis is that in cancerous cells, the inhibition of Heat Shock 
Protein 90(HSP90) might induce the expression of HSP90 and HSP70. The 
secondary hypothesis is that comparing the effects of 17-AAG and Radicicol 
treatment between A549 cells and Mesenchymal Stem Cells (MSC) can help us in 
screening the drugs effectively.  
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1.3 Overall Objective 
The primary goal of this project is to analyze on a proteomic scale the effect of 
HSP90 inhibition with 17-AAG and Radicicol on cancerous lung cells. If we 
inhibit HSP90 it would be beneficial for all types of cancer including the most 
metastatic late-stage tumors with a broad-spectrum of activity. We are targeting 
the HSP90 and HSP70, which act as, co-chaperon for various client proteins 
involved in cancer progression by effecting the expression of various client 
proteins that are relevant to tumor growth. The client proteins of the HSP90 
complex include v-Src, Akt, Raf-1, Bcr-Abl, ErbB2, mutant p53 and hypoxia–
inducible factor-1α. Therefore inhibiting HSP90 will eventually affect these client 
proteins, which will not be able to function properly, thereby helping to decrease 
the cancerous activity of the cells. Previous work has been done showing a change 
in the expression of the client proteins as an “on target” effect of the drug 
treatment (HSP90 inhibitors- 17AAG and Radiciol) as compared to an ineffective 
analogue of the drug. We are trying to study whether there is a change (increase/ 
decrease) in the expression of HSP90 and HSP70 in the drug treated cells as 
compared to the untreated cells. The effect of the drugs on Mesenchymal Stem 
Cells is also being tested. It is logical to say that the change in expression of the 
chaperones; HSP90 &HSp70 affects the expression of their client proteins.  
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Fig 1.1: Examples of roles of Hsp90 and its co-chaperones in different cellular 
processes through their interaction with client proteins.(Caplan, et al., 2003). 
 
Previous work done by Maloney et al. shows an increased expression of various 
client proteins like c-RAF1 using microarray analysis and 2-D Gel 
Electrophoresis, when human ovarian cancer cells are treated with 17AAG and 
Radicicol as compared to an inactive analogue.  HSP90 and HSP70 can also be 
the on-target effects of HSP90 inhibition. These drugs compete with ATP to bind 
at the N-terminal end of HSP90 and therefore alter many of the normal functions 
of HSP90, one of them being chaperoning the client proteins. As these drugs do 
not allow ATP to bind at the N-terminal end of HSP90, the HSP90 complex is 
disrupted. The disruption of the complex, the basis of which is formed by HSP90 
& HSP70 leads to an increased expression of HSP90 and HSP70. An attempt has 
been made to validate this with proteomic analysis with traditional techniques like 
Western Blotting. 
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Figure 1.2: The binding of a client protein to HSP90 requires the co-operation of 
HSP90 with another chaperone, HSP70 and its co-factor HSP40. Both HSP90 and 
HSP70 chaperones are further linked by an adapter protein called HOP, which 
binds to both HSP90 and HSP70 through the small helical TPR domains to the C-
terminal ends of HSP90 and HSP70. Aha1 is a co-factor that can bind and 
stimulate activity of HSP90 ATPase. When HSP90 exchanges ADP for ATP, it 
undergoes conformational change, which dissociates from the 
HSP70/HSP40/HOP complex, allowing ATP-dependent interaction with other co-
chaperones, such as CDC37 and p23, to form a mature complex. It is in this 
mature state that HSP90 that allows client protein activation following cellular 
stresses, including phosphorylation of AKT, binding of EGFR to its ligands and 
ensuring transcription factors, such as HIF-1 and p53, to express genes. Inhibition 
of ATP-binding through HSP inhibitors prevents client protein maturation and 
result in degradation of these oncogenic proteins by the proteasome (Mahalingam, 
et al., 2009). 
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 The specific aims of this particular project are: 
• To use proteomic analysis (Mass Spectrometry) as a technique to 
quantify the over expression of HSP90 and HSP70. Also we are using 
kinetic-labeling using mBBR for the Mass Spec. The over expression 
of the proteins is seen as an on-target effect of HSP90 inhibition due to 
the drugs- 17AAG and Radicicol. 
• To perform a quantitative analysis by Western Blotting to validate the 
Mass Spectrometry findings. Also to check the effect of various 
concentration of the drugs. 
• To check the rate of recovery of cells after the drug treatment.  
Proteomic picture after the drug treatment would ascertain the 
mechanism of action of the drugs. 
• To compare the results of drug treated A549 cells with Mesenchymal 
Stem Cells (MSC) to study the effect of drugs on primary cells apart 
from cell line. Also checking the morphology of the cells before and 
after drug treatment would help in understanding the dose response. 
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Chapter 2. Background Information   
 
     2.1. Heat Shock proteins (HSP) & Cancer 
 
Heat shock proteins are also known as stress proteins. They are a major class 
of molecular chaperones proteins that play a vital role in cellular stress 
response and cancer (Calderwood & Ciocca, 2008). They are a family of 
highly conserved group of proteins, are ubiquitous and are found in every cell 
and tissue (L. Whitesell & S. L. Lindquist, 2005). HSPs are categorized into 
several families based on their molecular weights and are induced when a cell 
undergoes various types of stress such as hypoxia, nutrient deprivation, and 
decrease in pH and increase in heat. Their role, however important is thought 
to be simply “housekeeping”. HSP’s are grouped in the family of chaperones 
because they provide functions such as assistance in general protein folding, 
assistance in conformational maturation of proteins and also to protect 
proteins from becoming misfolded as a result of environmental insults (L. 
Whitesell & S. L. Lindquist, 2005). 
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Figure 2.1: Participation of molecular chaperones in regulating many aspects of 
post-translational protein homeostasis. Dynamic association of a client with 
chaperone complexes can (a) prevent its aggregation (b) assist in intracellular 
trafficking (c) help to maintain the protein in a meta-stable state so that they can 
be activated by specific stimuli like ligand binding or phosphorylation for signal 
transduction pathways (d) target the client for degradation through ubiquitin - 
proteasome pathway, thereby regulating its steady state cellular level (Luke 
Whitesell & Susan L. Lindquist, 2005). 
 
 
   The essential chaperoning functions of HSP’s are subverted during oncogenesis 
to make malignant transformation possible and to facilitate rapid somatic 
evolution. Functioning as biochemical buffers for the numerous genetic lesions 
that are present within tumors, chaperones, especially HSP90, allow mutant 
proteins to retain or even gain function while permitting cancer cells to tolerate 
the imbalanced signaling that such oncoproteins create. 
HSP’s are classified by their molecular weight, size, structure and function. 
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    HSP 70                                                           HSP 90                                                
                                                     
      HSP 60                                                          HSP27  
Figure 2.2:  Different members of heat shock protein family 
 Heat Shock Proteins also prevent misfolding and aggregation of polypeptides 
while they exit the ribosome (Hartl, 2002). HSP expression becomes deregulated 
in cancer leading to elevated expression. Elevated HSP expression effects cancer 
by inhibiting programmed cell death (change in expression of HSP70) and by 
promoting autonomous growth (HSP90) and leads to resistance to chemotherapy 
(Calderwood & Ciocca, 2008). 
2.2 HSP 90 
2.2.1 Mechanism of HSP90 activity 
One particular chaperone, HSP 90 is gaining a lot of interest as potential cancer 
therapeutic target. During oncogenesis the guardian function of HSP90 to 
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maintain the conformational stability and function of a number of oncogenic 
“client” proteins required for cellular proliferation, cell cycle regulation, 
apoptosis, invasion, angiogenesis, and metastasis is transformed (Luke Whitesell 
& Susan L. Lindquist, 2005). Since it is the function of HSP90 to protect proteins 
from environmental stress, it seems logical to say that HSP90 expression is up 
regulated in stressful conditions.   
HSP90 is expressed at high levels in a wide variety of human cancers 
including melanoma, leukemia, and cancers in colon, prostrate, lung and breast. 
HSP90 comprise as much as 1-2% of total cellular protein content and this 
amount increases about two fold under stress (L. Whitesell & S. L. Lindquist, 
2005). Therefore inhibition of HSP90 can suppress certain cancer causing client 
proteins and therefore can be a potential therapeutic target. There are two closely 
related cytoplasmic isoforms of HSP90, HSP90AA1 (HSP90α, inducible form) 
and HSP90AB1 (HSP90β, constitutive form). Both the isoforms are 76% identical 
in primary amino acid sequence. The other two HSP90 family members are 
endoplasmic reticulum protein (Grp94) and Trap-1 protein, which localizes in 
mitochondria. The cytoplasmic HSP90 consists of three functional domains: 
• N-terminal ATPase domain (which is targeted by 17 AAG and Radicicol) 
• Middle domain (amino acids 273-560), which is highly charged and 
participates in the catalytic mechanism essential for ATPase activity and is 
implicated in client protein binding 
•  C-terminal dimerization domain that also binds to ATP (L. Whitesell & S. 
L. Lindquist, 2005). 
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Figure 2.3: Structure of HSP90 dimer. ‘CR’ refers to a charged region which 
serves as a flexible linker between the N-terminal and middle domain (L. 
Whitesell & S. L. Lindquist, 2005). 
 
The client proteins, those protected by HSP90, are a variable “who’s-who” of 
signaling proteins involved in malignancy. The effects of HSP on the anabolic 
pathways leading to self-sufficiency in growth signals are mediated largely 
through HSP90. This molecular chaperone is essential for the stability of the 
fragile structures of many receptors, protein kinases, and transcription factors that 
lie along the pathways of normal cellular growth. HSP90 is required to maintain 
signaling proteins in active conformation that can be rapidly triggered by growth 
signals. This chaperone may thus be viewed as a facilitator of the rapid responses 
to extracellular signals required, particularly in development and self-renewal. 
Transformation of HSP90 involves over expression or mutation of many of these 
HSP90 dependent signaling molecules. Hence, HSP90 is increasingly required to 
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maintain such proteins in active conformation. HSP90 is essential for the stability 
and activity of over 200 HSP90 clients (Neckers, Len a; Ivy, S. Percy b, 2003). 
 
Table 1: Various client proteins that require HSP90 for protection, stabilization 
and maturation (Mahalingam, et al., 2009). 
Protein Name  Category of protein Mechanism of action 
p53 Signaling protein 
(mutated and chimeric) 
Transcription of genes involved in 
cell cycle arrest 
v-Src Signaling protein   
BCR-ABL Signaling protein  Activates signal transduction 
NPM-ALK Signaling protein  Induces cell transformation & 
proliferation 
Akt Metastable signaling 
protein kinases 
Activation of prosurvival proteins 
& suppression of pro apoptic 
proteins 
ErbB2, EGFR 
 
Transmembrane 
kinases 
Activation of downstream 
prosurvival pathways; MAPK 
EGFR Transmembrane 
kinases 
Activation of downstream 
prosurvival pathways; P13K-AKT 
Cdk4- Cdk6 Cell cycle regulators Phosphorylates & inactivates Rb 
allowing cell cycle to proceed 
HIF-1a Transcription factor Promotes angiogenesis 
MMP2  Facilitates invasion through cell 
adhesion, matrix digestion 
B-Raf mutant Signaling kinase Activates ERK signaling 
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The diverse intracellular roles for HSP90 have led to a theory of “oncogene 
addiction” (Weinstein, 2002). Through mutations, cancer cells become dependent 
on oncogenic pathways. Then the most malignant tumor cells are selected for 
cloning. As this malignant process proceeds, there is a need for the up-regulation 
of HSP90. The dependency of the cancer cells on HSP90 increases to a great 
extent as HSP90 protects the over-expressed and unstable oncogenic proteins. 
Therefore, it makes sense to say that if we inhibit HSP90 it would be beneficial 
for all types of cancer including the most metastatic late-stage tumors with a 
broad-spectrum of activity (Maloney, et al., 2007) (Jin et al., 2011). 
2.2.2 HSP90 does not act alone 
HSP90 binds to client proteins after forming an intermediate complex with co-
chaperones like HSP70, HSP40, HIP and HOP (Caplan, et al., 2003). HSP90 
interacts with co-chaperones in a highly ordered series of dynamic multi-protein 
complexes that are linked to conformationally coupled ATPase cycle 
(C.Prodromou et al., 2000). Upon ATP binding and hydrolysis, HSP90 forms a 
mature complex containing p23, cdc37 and immunophilins that catalyze the 
conformational maturation and release of the client protein so that HSP90 can 
begin this cycle again. 
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Figure 2.4: Co-chaperones of Hsp70 and Hsp90 enter and exit chaperone–GR 
(glucocorticoid receptor) protein complexes in a defined order. This cycling 
reflects the co-operation between Hsp70 and Hsp90, and the role of different co-
chaperones, for example p23, Hsp40, Hip, Hop and others, such as 
immunophilins, in the folding process. The GR protein is shown in green. H, 
hormone; C, other co-chaperones, for example immunophilin, FKBP51, FKBP52, 
CyP40 and PP5 (Caplan, et al., 2003). 
 
It has been shown that there is an increase in expression of both the major 
constitutive heat shock cognate 70 (HSC70) and inducible isoform HSP72 after 
HSP90 inhibition using microarray, 2-D Electrophoresis and siRNA silencing. As 
shown by Power et al. 2008, depletion of both these isoforms using short 
interfering RNA (siRNA) before HSP90 inhibition enhances HSP90 inhibitor 
cytotoxicity (Powers, Clarke, & Workman, 2008). HSP70 can be considered as a 
pharmacodynamic marker of HSP90 inhibition in both tumor tissue and peripheral 
blood lymphocyte (Modi et al., 2007). Following this a preclinical study 
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suggested that serum HSP70 levels could be considered as useful 
pharmacodynamic marker of drug response. The study was based on enzyme-
linked immunosorbent assay (ELISA) and made it clear that HSP70 increased 
several fold in tumor xenograft-bearing mice, following treatment with HSP90 
inhibitors, perhaps owing to tumor lysis (Dakappagari et al., 2010). Although the 
expression of HSP70 due to HSP90 inhibition helped to established biologically 
active drug dosing, nothing is clear about its co-relation with the clinical response 
(Kummar et al., 2010). The question that does the induction of HSP70 following 
HSP90 inhibition attenuates the cytotoxic effects of HSP90 inhibitors or decreases 
HSP90 inhibitor efficacy still remains unclear.  
2.2.3 HSP90 inhibitors in Clinical Trials 
With promising but complicated pre-clinical data, several HSP90 inhibitors 
entered human clinical trials. Today there are about 13 HSP90 inhibitors 
undergoing Clinical Evaluation and 23 active HSP90 inhibitor oncology trials. 
Several chemically distinct HSP90 inhibitors with improved properties including 
oral biological availability in Clinical trails are shown. 
Table 2: HSP90 Inhibitors currently in Clinical Trials (Kim et al., 2009). 
Inhibitor Phase Route Source 
17 AAG I/III Intravenous BMS 
IpI-504 II Intravenous Infinity 
BIIB021 
CNF2024 
II Oral Biogen Idec 
AUY922 I/II Intravenous Novartis 
STA-9090 I/II Intravenous Synta 
IpI-493 I Oral Infinity 
SNX-5422  I Oral Pfizer, Inc. 
BIIB028 I Intravenous Biogn Idec 
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Inhibitor Phase Route Source 
KW-2478 I Intravenous Kyowa Hakko 
Kirin 
AT13387 I Oral or 
Intravenous 
Astex 
Therapeutics 
XL888 I Oral Exelixis 
HSP990 I Oral Novartis 
ABI-010 I Intravenous Abraxis 
Bioscience 
 
 
Although currently there are no approved HSP-90 targeted drugs, there has been 
progress on several fronts. The potential for using HSP90 inhibitors as anticancer 
agents is exciting and its theoretical uses seem almost endless. Most of these 
clinical trials are in patients with refractory, late stage disease, which means that 
these patients have failed all other standard therapies. 
2.2.4 Affinity of HSP90 inhibitors towards cancer cells 
HSP90 inhibitors, which act as biologic probes, prove that cancer cells are 
significantly more sensitive to HSP90 inhibition than non-transformed cells (Solit, 
2008). The selective sensitivity of transformed cells for HSP90 inhibitors may be 
partly due to selective accumulation of these drugs in cancer cells. The selective 
accumulation of HSP90 inhibitors in tumors has been reported with compounds 
that display little structural homology and diverse solubility profiles. One possible 
explanation for this result is that the binding affinity for these compounds may be 
higher for tumor derived HSP90 than HSP90 derived from non-transformed cells 
because of higher abundance of activated, co-chaperone bound HSP90 found in 
tumor. Inhibition of HSP90, therefore affects simultaneously multiple 
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transforming molecules and pathways. Cancer selectivity is a unique and 
therapeutically attractive feature of targeting this chaperone.  
2.2.5 HSP90 inhibitors: 17AAG and Radicicol 
Geldanamycin was the first ansamycin derived HSP90 inhibitor. Shortly after the 
discovery of Geldanamycin, it was proved of not having a sufficient therapeutic 
window due to hepatotoxocity (Banerji and Workman, 2003). The demethyl 
derivative of geldanamycin (17AAG) exhibited an improved therapeutic window 
and showed promising inhibition of tumor growth at well tolerated doses 
(Workman, 2004). The toxicity was associated with the quinine metabolism 
(Seddon, 2003). Today 17-AAG is undergoing Phase III evaluation with an 
improved formulation that overcomes several toxicities that were common to 
earlier clinical trial. 17-AAG binds at the N-terminus of HSP90 and alters many 
of its normal functions. In particular, a drug bound HSP90 seems to recruit E3 
ubiquitin ligases such as CHIP (carboxy-terminus of HSP70-Interacting protein) 
to many client proteins that are normally chaperoned by HSP90 containing multi-
protein complexes (Xu, 2002). This recruitment leads to increased proteasome-
mediated degradation of the clients and depletion of their cellular levels. The 
pharmacological mechanism of 17-AAG is to compete against ATP in a distinct 
3-D conformation, which is only found in cancer, thereby reducing the protection 
of oncogenic client proteins. Also, 17-AAG leads to depletion of certain over 
expressed growth factor receptor, for example ERBB2 in certain breast cancer. 
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2.3 Proteomics 
The proteome is the entire set of proteins expressed in a given type of cells or an 
organism at a given time under a particular set of conditions (Petricoin, Zoon, 
Kohn, Barrett, & Liotta, 2002). Large-scale study consisting of characterizing and 
analyzing the proteins, their structure and function and the protein-protein 
interactions is collectively known as proteomics. Although all cells have the same 
genome and the genome often stays constant over many years, the proteome 
varies with cell type. Even within one cell type the proteome can fluctuate over 
time and is greatly influenced by external and internal environmental conditions. 
Matthias Maan and Rudi Aebersold defined proteomics as “the ability to 
systematically identify every protein expressed in a cell or tissue and determine 
the salient properties of each protein, i.e. abundance, state of modification and 
involvement in multi-protein complexes” (Aebersold, 2003). However, in practice 
it is important to study comparative proteomics, specifically, what has changed, 
appeared, disappeared or shifted in concentration between normal and distorted 
(Regnier et al., 2002). The great strength of proteomics is being able to perform 
the systematic analysis simultaneously of all the proteins in a complex system. 
Proteomic approaches have a great potential in drug development process.  
2.4 Mass Spectrometry 
Mass Spectrometry is used for systematic study of proteins expressed in a cell or 
tissue. As the workhorses of proteomics, mass spectrometers measure mass to 
charge ratio (m/z). As a technique Mass Spectrometry dominates the field of 
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proteomics due to its tremendous advantages over other techniques for 
unambiguous identification of proteins. Mass Spectrometers have three main 
components:  
• An ionization device for the transfer to gas phase of analytes while 
maintaining or acquiring charge. 
• A mass separator which can only separate charged molecules in the gas 
phase  
• The detector 
A mass spectrometer can separate ions very precisely from a collection of 
other ions and is therefore a very powerful tool to analyze complex peptide 
mixtures (Aebersold, 2003). It is thereby increasingly becoming the method of 
choice for analysis of complex protein samples. Protein analyses (primary 
sequence, post-translational modification or protein-protein interactions) by 
Mass Spectrometry have been most successful when applied to small sets of 
proteins isolated in specific functional context (Aebersold, 2003). The effects 
of HSP 90 inhibitors 17-allylyamino-17-demethoxygeldanamycin (17 AAG) 
and Radicicol can be studied using Proteomics for their anti-tumor effect. The 
degradation of the HSP90 client proteins via the ubiquitin-proteasome 
pathway has already been studied (Maloney, et al., 2007). 
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2.5 A549 cells and Mesenchymal Stem Cells (MSC) 
A549 cell line was initiated by D.J. Giard, et al. through explant culture of lung 
carcinomatous tissue from a 58-year-old Caucasian male in 1972.   
Figure 2.5: A-549 Lung epithelial carcinoma cells 
Friedenstein et al first isolated mesenchymal stem cells in 1974. They are primary 
adult stem cells that can differentiate into adipocytes, chondrocytes, 
cardiomyocytes and neurons. MSC’s are fibroblastoid cells and are spindle-
shaped. They have a high growth potential and are adherent to tissue culture glass 
or plastic.  
 
Figure 2.6: Mesenchymal Stem Cells (Mok & Cheong 2002). 
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Chapter 3- MATERIALS AND METHODS 
 
3.1 Sample Preparation  
A549 cells were obtained from American Type Tissue Culture Collection 
(Rockville, MD). 17-AAG was bought from LC Laboratories, 165 Boston Street, 
Woburn, MA, 1801. Radicicol was obtained from Sigma Chemical Co. (Poole, 
United kingdom). Cells were grown in F12 HAM media containing 10% fetal 
bovine serum, 200mmol/L L-Glutamine and 1% nonessential amino acids (Life 
Technologies, Paisley, United Kingdom) in a humidified atmosphere of 5% CO2, 
/95% air at 37°C. Cells were seeded at 106 cells/flask and allowed to proliferate 
till they attained 70% confluency. Cells were treated for 24 hours with 
pharmacologically relevant, isoeffective concentrations of 17AAG (60nM) and 
Radicicol (600nM) in 10mL medium. DMSO was added to a flask as Control 
sample. After a period of 24hours cells were harvested using 0.05% Trypsin-
EDTA (Life Technologies, Paisley, United Kingdom). Control cells were set up in 
triplicate and 17-AAG treated cells were set up in duplicate. Additional dishes 
were set up for Western blotting analysis.  
3.2 Kinetic labeling and In-Gel Electrophoresis  
Kinetic labeling was performed after harvesting the cells with trypsin-EDTA (Life 
Technologies, Paisley, United Kingdom).  Cells were washed three times in ice 
cold PBS. After counting them on a haemocytometer they were suspended in 
labeling buffer (PBS). The PBS was added in such a way that the cells/volume 
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ratio remains constant in both the untreated and the 17-AAG treated samples. The 
resuspended cells were split in eppendorf tubes to be labeled with 20µl of 500µM 
monobromobimane (mBBR, a thiol selective dye). The labeling dye was 
quenched with 2µl of 100mM glutathione at time intervals of 3min, 8min, 13min, 
20min, 30min, 60min and a control with no label added to it. Samples were stored 
at -20°C. 
3.3 In –Gel Digestion, and sample preparation for LC-MS/MS  
After the samples were labeled at 3min, 8min, 13min, 20min, 30min and 60 min 
for both the untreated and 17-AAG treated samples, they were loaded on the gel 
for separation by conventional sodium dodecyl polyacrylamide gel 
electrophoresis (PAGE).  The gel was stained using Coomassie dye (Life 
Technologies, Paisley, United Kingdom) & imaged using HP Scanjet 4850 
scanner. The image was analyzed using Adobe Photoshop5 and scanned with 
TWAIN32 driver. The image of the gel was printed out and the required bands 
were identified. In a clean work area the bands were excised using razor blade and 
were placed in pre-labeled 500µl clean eppendorf tubes. The gel slices were 
washed with 200µl of 0.2M ammonium bicarbonate and 50% acetonitrile to 
remove the excessive coomassie dye. The gel slices in the eppendorf tubes were 
lyophilized in the lyophilizer at a temperature of -50°C and a pressure of 10Pa for 
a period of 15 minutes. The gel slices were incubated with 100µl of 20mM TCEP-
HCL and 25mM ammonium bicarbonate for 20 minutes. 100µl of 40mM 
iodoacetamide was added as an alkylating agent. The gel slices were washed with 
ammonium bicarbonate and 15% acetonitrile, lyophilized (Labconco, Kansas 
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City, MO) and digested with sequencing grade modified trypsin (Promega, 
Madison, WI) and were hence ready for LC MS-MS. The prepared samples were 
submitted to the Center for Systems and Computational Biology at the Wistar 
Institute, Philadelphia for LC-MS/MS. 
3.4 SDS-PAGE and Immunoblotting 
For immunoblotting, 17AAG & Radicicol & DMSO treated A549 cells were 
harvested with Trypsin–EDTA (Life Technologies, Paisley, United Kingdom), 
The samples were washed three times in ice cold Phosphate buffered saline, 
counted and lysed in lysis buffer (RIPA buffer; 150mM NaCl, 1% NP40, 0.5% 
Sodium Deoxycholate, 0.1% SDS, 50mM Tris) and centrifuged at 14,000*g, and 
the supernatant was recovered. 
Two different concentrations of drugs were tested in order to check the toxicity of 
drug and recovery of the cells after the treatment. 30nM and 60nM concentration 
of 17AAG and 300nM and 600nM concentration of Radicicol were tested. Protein 
was extracted from each concentration of drug treated cells. The protein 
concentration in each sample was determined using a bicinchoninic acid (BCA) 
protein assay (Pierce, Rockford, IL). The solution absorbance at 560nM was 
measured in triplicates, averaged, and the amount of protein was estimated. 
Protein from each cell sample (15µg, 20µg and 30µg of each) were denatured in 
Laemmli loading buffer (10% glycerol, 5% β-mercaptoethanol, 2% SDS, 
62.5mmol/L Tris (ph=6.8), 0.05% bromophenol blue)(NuPAGE LDS Sample 
Buffer, Invitrogen, Carlbad, CA) followed by 10minute spin down at 14,000*g in 
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24	  
a mini centrifuge (Spectrafuge, Labnet, Interna Inc.). Protein samples were 
separated on 4-20% Bis-Tris gel (1.0 mm thick, 10-well) (NuPAGE Novex® gels, 
Invitrogen, Carlbad, CA) and transferred to a nitrocellulose membrane 
(Invitrogen, Carlsbad, CA). Novex® Sharp Pre-stained Protein Standard 
(Invitrogen, Carlsbad, CA) were used to estimate molecular weights. The 
following primary antibodies and dilutions were utilized: mouse IgG HSP90 
(1:1000 dilution), mouse IgG HSP70 (1:1000 dilution) and mouse IgG β-Actin 
(1:1000 dilution). All the three antibodies were obtained from AbCam 
(Cambridge, MA). Membranes were washed twice with PBS containing 0.05% 
Tween 20(Fisher Scientific). Probing with anti-mouse IgG horseradish peroxidase 
(GE Healthcare, Burmighamshire, UK) at 1:2000 dilutions did visualization of the 
bound primary antibody. The membrane was washed four times and 
immunodetection was carried out using enhanced chemiluminescence reagent 
(Genscript Chromosensor, TMB substrate) and imaged by HP Scanjet 4850 
scanner.  
3.5 In vitro Inhibition studies with 17-AAG and Radicicol 
Cells were seeded in fresh media (1ml) at 1 *106 cells per flask in a T-75 and were 
allowed to proliferate and attach for a day, after the drug treatment of 24 hours the 
cells were harvested and counted for in vitro cellular assays. 17-AAG (LC 
Laboratories, 165 Boston Street, Woburn, MA, 1801) and Radicicol (Sigma 
Chemical Co., Poole, United kingdom)) were stored at -20°C until used. They 
were then diluted with DMSO to a concentration of 60nM for 17AAG and 600nM 
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Radicicol. (Maloney, et al., 2007). Aliquots of treated cells were analyzed for cell 
viability and proliferation using microscope (Nikon).  
3.6 Imaging Mesenchymal Stem Cells before and after drug treatment 
The MSC’s were imaged using Olympus IX-71, Phase contrast inverted 
microscope. The 20X lens was used to study the morphology of the cells before 
and after drug treatment whereas the 4X lens was used to check the confluency of 
the cells. The phase level of the microscope was adjusted to 2 and the 
fluorescence level was adjusted to 6. Photometric Cascade 512B by Roper 
Scientific was used to capture the images of the cells and Image Pro software was 
used to save the images. 
3.7 Qualitative Analysis 
3.7.1. Cell Culture Techniques 
90µl of the cell suspension of both the untreated and drug treated cells was mixed 
with 10µl of Trypan blue solution each. 10µl of this solution was loaded on the 
hemocytometer. Only the healthy cells were counted, i.e. the ones in which dye 
did not permeate the cell membrane. The numbers of cells were counted using the 
formula:Number of cells/mL=(average # cells per big square)*104 . 
4.7.2. Intensity Analysis 
The analysis of the Western Blot bands was performed using ImageJ software 
(National Institute of Health). 
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Chapter 4. EXPERIMENTAL DESIGN 
 
The experiment consisted of a proteomic approach (Mass Spectrometry) and the 
traditional Western blotting technique to quantify the increased expression of 
HSP90 and HSP70 upon drug treatment. The A549 cells were given the drug 
treatment for a period of 24 hours. Whole cell lysates, of control and drug treated 
cells were separated by SDS-PAGE and required protein bands were identified 
and excised for mass spectrometry. For the immunoblotting analysis after the 
samples were run on SDS PAGE, they were transferred to a nitrocellulose 
membrane. The membrane was stained with HSP90 and HSP70 antibodies. The 
immunoblotting experiment was repeated with Mesenchymal Stem cells (MSC’s) 
to study the effect of drugs on primary cells as compared to cancer cell line. Both 
analyses were performed in duplicates for averaging purposes. The western blot 
analysis was normalized against β-Actin. 
4.1 Criteria for using kinetic labeling 
Reactive amino acids like cysteine can be labeled with fluorescent molecules like 
mBBR. By looking at the changes in the amount of labeling, we identified the 
proteins that undergo conformational changes upon 24 hour of 17-AAG 
treatments. Cysteines that are buried in the core of a protein will not react as 
quickly as those on the surface so looking at the fraction of cysteines that are 
labeled in different domains of HSP90 of the drug treated and untreated samples 
is used to estimate those cysteines exposure. Cysteine residues are found at 
various locations n HSP90. Cysteine residue numbers referring to a rat Hsp90α 
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are Cys-366, Cys-412, Cys-521, Cys-564, Cys-589, Cys-590 (Nardai, Sass, Eber, 
Orosz, & Csermely, 2000). mBBR was the fluorescent tag that reacted with thiol 
containing compound- glutathione.  
4.2 Criteria for using LC MS-MS 
Ratiometric measurements should be made relative to a standard. Data is 
conventionally normalized against the total amount of protein or against a 
housekeeping protein with concentration assumed to be invariant between 
conditions. LC-MS/MS has the flexibility to allow either of these options.  
Additionally the limitation of using Western Blotting for protein quantification is 
that it depends on antibody availability. It has been possible to find a binding 
system for almost any antigen and over last 10 years, large antibody libraries have 
become commercially available. However, the quality and reliability may be 
variable. Different antibodies ostensibly binding the same protein, or more 
specifically different regions of same protein may give different or contradictory 
results (Vellaichamy, Lin, Aye, Kunde, & Nesvizhskii, 2010). Detection of an 
intended target protein may not be specific if other proteins have domains similar 
to that intended by the antibody. These problems are exacerbated further when 
isoform differentiation is required, potentially requiring antibody specificity to 
change in a few amino acids, or cases where species specificity is nedded. LC-
MS/MS allows proteins to be accurately identified based on sequence of amino 
acids within tryptic fragments. Because mass spectrometry allows samples to be 
characterized on the basis of their amino acid sequence, LC-MS/MS was used to 
identify tryptic fragments unique to isoform, species. 
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Figure 4.1: Mass Spectrometry analysis protocol used.(Aebersold, 2003) 
4.3 Criteria for using Western Blotting 
With chemiluminescence, Western blot experiments can be extremely sensitive, 
with even femto-gram detection being possible (Alegria-Schaffer, Lodge, & 
Vattem, 2009). Modern LC-MS/MS instruments are not quite so sensitive.  For 
analyzing drug treated and untreated mesenchymal stem cells Western blotting 
proved to be effective as even 2µg of protein was detected. 
 4.4 Selection and optimization of an invariant control set 
When quantifying any change in protein levels, it is imperative to define what 
change is being measure relative to. It may be desirable to normalize against the 
number of cells, total protein content, total DNA content, or against a selected 
“housekeeping” protein that is deemed to be invariant during pertubation. Two 
options are considered for standardization of immunoblotting and established 
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mass spectrometry techniques: total protein or selecting a single, standard protein. 
Generally in Western blot experiments calibration is done against total protein, 
lanes in a gel are loaded with successive dilutions of the same sample (i.e. varying 
the total protein concentration). A second approach used is choosing a standard 
protein that is present at same level in each sample. In Western blot analysis 
staining is done for a ‘housekeeping’ protein, usually β-Actin. Studies that look 
directly at Western Blotting have shown that GAPDH levels vary significantly as 
cells approach confluency, and that in such cases β-Actin is a better candidate for 
standardization (Greer, Honeywell, Geletu, Arulanandam, & Raptis, 2010). 
A significant body of work has been published in the field of RNA quantification 
by RT-PCR that searches for a set of constitutive ‘housekeeping genes’ for a 
similar purpose of normalization. A list of typical reference genes might encode 
for: glyceraldehydes-3-phosphate dehydrogenase (GAPDH), albumin, β and Υ-
actins, α andβ tubulins, cyclophilin, hypoxantine phosphoribosyltransferase  
(HRPT) and L32 (Thellin, ElMoualij, Heinen, & Zorzi, 2009). To use these 
proteins as standardization for a proteomics experiment would be to make an 
assumption that RNA and protein levels are directly analogous. 
 4.5 Constraints in Experimental Design 
The current study focuses on the increased expression of HSP90 and HSP70 upon 
drug treatment. The reason behind greater induction of HSP70 upon HSP90 
inhibition needs to be studied in detail. Moreover, the proteomic analysis (Mass 
Spectrometry) is used to study the effect of 17-AAG on A549 cells. The study 
lacks mass spectrometry results of Radicicol treated A549 cells or the drug treated 
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and untreated Mesenchymal Stem Cells. Also there is a comparison between 
primary cells (MSC) and cancerous lung epithelial cells.  The comparison 
between drugs treated and untreated cancerous lung epithelial cells and 
untransformed lung epithelial cells is lacking. The morphology and the cell 
number of MSC are included in the results. Minimal change in the cell 
morphology and cell number means that drug is not effective.  The variation in 
dosing and duration of drug treatment is lacking. 
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Chapter 5- RESULTS 
 
5.1 Proteomic analysis of 17-AAG treated A549 cells. 
After 24 hour of drug treatment the A549 cells were harvested. The whole cell 
lysates were analyzed using one -dimensional gel electrophoresis to detect 
changes in the A549 proteome following 17AAG treatment. Figure 6.1 shows a 
gel image of 17-AAG treated and untreated A549 cell lysates. 
The bands ranging from 110kD to 60kD were excised, 
(a)                                                              (b)
  
Figure 5.1.1: SDS PAGE gels of  (a) Control (b) drug treated (60nM of 17AAG) 
A549cell lysates, stained with Coomassie blue dye for MS analysis. 
 
The excised gel bands were kinetically labeled; trypsin digested and was submitted 
for Mass Spectrometry. A proteomic scale picture of the cells after the drug 
treatment was obtained with the help of the results from LC-MS/MS experiment. 
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Table 3: Percentage increase in proteins in 17-AAG treated samples as compared 
to untreated sample. 
Heat shock 70 kDa protein 1A/1B 723 
Heat shock protein HSP 90-alpha 191 
Heat shock cognate 71 kDa protein 157 
Stress-induced-phosphoprotein 1 138 
Plastin-3 138 
Exportin-2 Isoform 3 132 
Heat shock protein HSP 90-beta 128 
Heat shock-related 70 kDa protein 2 128 
Stress-70 protein, mitochondrial 125 
Transitional endoplasmic reticulum ATPase 115 
Importin subunit beta-1 112 
Protein disulfide-isomerase A4 106 
Mitofilin 105 
Lamin A/C 103 
78 kDa glucose-regulated protein 102 
Moesin 101 
Bifunctional purine biosynthesis protein PURH 101 
Nucleolin 96 
Trifunctional enzyme subunit alpha, mitochondrial 94 
ATP-dependent DNA helicase 2 subunit 1 92 
Nucleolar RNA helicase 2 85 
Elongation factor 2 84 
Probable ATP-dependent RNA helicase DDX5 62 
60 kDa heat shock protein, mitochondrial 44 
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Figure 5.1.2:Increased expressions of HSP90 & HSP70 in A549 cells following 
HSP90 inhibition, analyzed by LC-MS/MS. 
 
The results of the Mass Spectrometry experiment indicated: 
• Approximately 7 fold increase in the expression of inducible isoform of Heat 
Shock Protein70 (1A/1B) upon drug treatment. 
• Approximately 2 fold increase in the expression of HSP90α Upon 17-AAG 
treatments. 
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5.2 Western Blot Analysis of A549 cells 
5.2.1 Protein Estimation and Western Blot Analysis of A549 cells treated with 
varying concentrations of Radicicol, stained with HSP90. 
 
         NoDMSO DMSO  300nMRadicicol         600nMRadicicol     60nM 17AAG
 
           M         12µg      12µg        12µg      16µg       18µg       12µg         16µg        18µg      16µg        18µg     M 
Fig 5.2.1.1: HSP90 stained A549 cells. 
        
       NoDMSO DMSO   300nMRadicicol     600nMRadicicol          60nM 17AAG
       M        12µg         12µg        12µg         16µg        18µg      12µg       16µg         18µg        16µg         18µg          M 
Fig 5.2.1.2: β-Actin stained A549 cells. 
 
A549 cells are treated with 300nM and 600nM of Radicicol. No DMSO treated eclls are 
the negative control and DMSO treated cells are the positive control. The drug treated 
samples were run in triplicates. The last two lanes have 60nM 17-AAG treated samples. 
12µg of protein from the whole cell lysates of No DMSO, DMSO, 300nM radicicol and 
600nMRadiciol treated A549 cells is loaded and compared. The samples are stained 
with HSP90 antibody and normalized to β- actin. 
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Fig 5.2.1.3: Increased HSP90 expression in Radicicol treated and untreated A549 cells. 
 
Intensity analysis of the gel bands is done using ImageJ (NIH). The graph shows 
thatA549 cells after being treated with 600nM of Radicicol show approximately 1.7 
fold increase in the expression of HSP90. The error bars show the standard deviation of 
the intensity analysis readings between the three different proteins loading of 300nM 
drug treated and 600nM drug treated cells. The three different loadings are 12µg, 16µg, 
and 18µg of protein. There is an insignificant difference in the band intensities of 
300nM radicicol treated samples and 600nM Radicicol treated A549 cells. 
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5.2.2 Protein Estimation and Western Blot Analysis of A549 cells treated with 
varying concentrations of Radicicol, stained with HSP70. 
 
     NoDMSO DMSO     300nMRadicicol         600nMRadicicol     60nM 17AAG 
    M         12µg      12µg        12µg      16µg      18µg      12µg      16µg        18µg      16µg        18µg     M 
Fig 5.2.2.1: HSP70 stained A549 cells. 
 
 
   NoDMSO     DMSO   300nMRadicicol          600nMRadicicol       60nM 17AAG
       M        12µg         12µg        12µg         16µg        18µg      12µg       16µg         18µg        16µg         18µg          M 
Fig 5.2.2.2: β-Actin stained A549 cells. 
 
 A549 cells are treated with 300nM and 600nM of Radicicol. No DMSO treated eclls 
are the negative control and DMSO treated cells are the positive control. The drug 
treated samples were run in triplicates. The last two lanes have 60nM 17-AAG treated 
samples. 12µg of protein from the whole cell lysates of No DMSO, DMSO, 300nM 
radicicol and 600nMRadiciol treated A549 cells is loaded and compared. The samples 
are stained with HSP70 antibody and normalized to β- actin. 
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Fig 5.2.2.3: Increased HSP90 expression in Radicicol treated and untreated A549 cells. 
 
Intensity analysis of the gel bands is done using ImageJ (NIH). The graph shows that 
A549 cells after being treated with 600nM of Radicicol for 24 hours show 
approximately 2fold increase in the expression of HSP70. The error bars show the 
standard deviation of the intensity analysis readings between the three different protein 
loadings of 300nM Radicicol treated and 600nM Radicicol treated cells. The three 
different loadings are 12µg, 16µg, and 18µg of protein. There is an insignificant 
difference in the band intensities of 300nM radicicol treated samples and 600nM 
Radicicol treated A549 cells. The number of samples we have is 3 so a T-test is not 
performed. 
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5.2.3 Protein Estimation and Western Blot Analysis of A549 cells treated with 
varying concentrations of 17-AAG, stained with HSP90. 
                            NoDMSO      DMSO               30nM 17AAG      60nM 17-AAG
	  M	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Fig 5.2.3.1: HSP90 stained A549 cells. 
 
                            NoDMSO      DMSO                  30nM 17AAG      60nM 17-AAG	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  14μg	  
Fig 5.2.3.2: β-Actin stained A549 cells. 
 
 A549 cells are treated with 30nM and 60nM of 17-AAG. No DMSO treated eclls are 
the negative control and DMSO treated cells are the positive control. The drug treated 
samples were run in triplicates and control samples are run in duplicates. 14µg and 16µg 
of protein from the whole cell lysates of No DMSO, DMSO, and 30nM 17-AAG and 
60nM17-AAG treated A549 cells are loaded and compared. The samples are stained 
with HSP90 antibody and normalized to β- actin. 
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Fig 5.2.3.3: Increased HSP90 expression in 17-AAG treated and untreated A549 cells. 
 
Intensity analysis of the gel bands is done using ImageJ (NIH). The graph shows that 
A549 cells after being treated with 60nM of 17-AAG show approximately 1.6 fold 
increase in the expression of HSP90. The error bars show the standard deviation of the 
intensity analysis readings between the three different proteins loading of 300nM drug 
treated and 600nM drug treated cells and two different protein loadings of the control 
sample. The three different loadings are 14µg, 16µg, and 18µg of protein. There is an 
insignificant difference in the band intensities of 30nM 17-AAG treated samples and 
60nM 17-AAG treated A549 cells. This HSP90 induction is comparable to the 
increased expression of HSP90 in 17-AAG treated A549 cells analyzed by Mass 
Spectrometry. 
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5.2.4 Protein Estimation and Western Blot Analysis of A549 cells treated with 
varying concentrations of 17-AAG, stained with HSP70. 
 
                            NoDMSO      DMSO                  30nM  17AAG      60nM 17-AAG	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Fig 5.2.4.1: HSP70 stained A549 cells 
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Fig 5.2.4.2: β-Actin stained A549 cells. 
 
A549 cells are treated with 30nM and 60nM of 17-AAG. No DMSO treated eclls are 
the negative control and DMSO treated cells are the positive control. The drug treated 
samples were run in triplicates and control samples are run in duplicates. 14µg and 16µg 
of protein from the whole cell lysates of No DMSO, DMSO, and 30nM 17-AAG and 
60nM17-AAG treated A549 cells are loaded and compared. The samples are stained 
with HSP70 antibody and normalized to β- actin. 
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Fig 5.2.4.4: Increased HSP70 expression in 17-AAG treated and untreated A549 cells. 
 
Intensity analysis of the gel bands is done using ImageJ (NIH). The graph shows that 
A549 cells after being treated with 60nM of 17-AAG show approximately 3fold 
increase in the expression of HSP90. The error bars show the standard deviation of the 
intensity analysis readings between the three different proteins loading of 300nM drug 
treated and 600nM drug treated cells and two different protein loadings of the control 
samples. The three different loadings are 14µg, 16µg, and 18µg of protein. The 17-AAG 
treated A549 cell samples analyzed by Mass Spectrometry show 7fold increase in the 
expression of HSP70 upon drug treatment. This means western blotting underestimates 
the increase in the induction of Heat Shock Protein 70. 
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5.3 Images of the MSC’s before and after 24 hours of Drug treatment 
 
 
Figure 5.3.1:Images of Mesenchymal Stem Cells before 24 hour of 17-AAG treatment. 
 
                  
          
Figure 5.3.2:Images of Mesenchymal Stem Cells after 24hrs of 60nM17-AAG 
treatments. 
There was hardly any change observed in the morphology and cell number of MSC 
before and after 24 hour of drug treatment.  
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5.4 Western Blot Analysis of Mesenchymal Stem Cells (MSC’s) 
 
5.4.1 Protein Estimation and Western Blot Analysis of MSC treated with 17-AAG 
and Radicicol, stained with HSP90. 
 
                                                 M             DMSO         No DMSO         600nM Rad     60nM 17-AAG 
                           
Figure 5.4.1.1 MSC stained with HSP90. 2µg of protein is loaded in each lane. 
 
                                                         M             DMSO         No DMSO         600nM Rad    60nM 17-AAG 
                         
Figure 5.4.1.2 MSC stained with β-Actin. 2µg of protein is loaded in each lane. 
 
 
Mesenchymal Stem Cells are treated with 600nM of Radicicol and 60nM of 17-AAG. 
No DMSO treated eclls are the negative control and DMSO treated cells are the positive 
control. 2µg of protein from the whole cell lysates of No DMSO, DMSO, and 600nM 
Radicicol and 60nM17-AAG treated Mesenchymal Stem cells are loaded and 
compared. The samples are stained with HSP90 antibody and normalized to β- actin. 
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Figure 5.4.1.3.  Intensity analysis with ImageJ of Western blot of MSC’s stained 
with HSP90. 
 Intensity	   analysis	   of	   the	   gel	   bands	   is	  done	  using	   ImageJ	   (NIH).	  The	  graph	   shows	  that	  MSC	  after	  being	  treated	  with	  60nM	  of	  17-­‐AAG	  show	  approximately	  1.07	  fold	  increase	  in	  the	  expression	  of	  HSP90.	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5.4.2 Protein Estimation and Western Blot Analysis of MSC treated with 17-AAG 
and Radicicol, stained with HSP70. 
 
                                                     M             DMSO         No DMSO         600nM Rad     60nM 17-AAG 
                         
Figure 5.4.2.1. MSC stained with HSP70. 2µg of protein is loaded in each lane. 
 
 
                                                         M             DMSO         No DMSO         600nM Rad    60nM 17-AAG 
                         
Figure 5.4.2.2. MSC stained with β-Actin. 2µg of protein is loaded in each lane. 
 
Mesenchymal Stem Cells are treated with 600nM of Radicicol and 60nM of 17-AAG. 
No DMSO treated eclls are the negative control and DMSO treated cells are the positive 
control. 2µg of protein from the whole cell lysates of No DMSO, DMSO, and 600nM 
Radicicol and 60nM17-AAG treated Mesenchymal Stem cells are loaded and 
compared. The samples are stained with HSP70 antibody and normalized to β- actin. 
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Figure 5.4.2.3.  Intensity analysis with ImageJ of Western blot of MSC’s stained 
with HSP70. 
 Intensity	   analysis	   of	   the	   gel	   bands	   is	  done	  using	   ImageJ	   (NIH).	  The	  graph	   shows	  that	  MSC	   after	   being	   treated	  with	   60nM	  of	   17-­‐AAG	   show	  approximately	   1.7	   fold	  increase	   in	   the	   expression	   of	   HSP70.	   	   This	   means	   that	   HSP90	   inhibiting	   drugs	  Radicicol	   and	   17-­‐AAG	   lead	   to	   an	   increased	   expression	   of	   HSP70	   even	   in	  untransformed	  primary	  cells.	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Chapter 6 -DISCUSSION 
 
 
The goal of this study was to assess the impact of inhibition of HSP90 in the cancer 
cells in vitro. Inhibition of HSP90 has received significant attention in cancer research 
due to its ability to retard or block tumor growth. It has been shown that HSP90 
inhibitors or compounds that bind to HSP90 can disrupt the cytosolic molecular 
chaperone complex resulting in the degradation of the client proteins. A derivative of 
Geldanamycin, 17-AAG and Radicicol are examples of HSP90 inhibitors currently in 
clinical trials. In the past, studies have shown that there is an increase in the expression 
of the client proteins of HSP90 complex if there is an inhibition of HSP90. Work done 
by Maloney et al. shows change in the expression of oncogenic client proteins like c-
Raf-1, PRMT5, ErbB2, CDK4 and AKT. The increase in the expression of HSC70, 
HSP72, HSP47 and HSp90β at mRNA level were studied with the help of microarray 
analysis and these proteins were considered to be the ‘on-target’ effect of HSP90 
inhibition.  MSC have never been used to study the effect of 17-AAG and Radicicol. 
This study uses two HSP90 inhibitors, 17AAG and Radicicol to study the proteomic 
scale effect of these inhibitors. The basic idea is that these drugs bind at the ATP 
binding site of HSP90 (the N-terminal end) and inhibit the formation of molecular 
chaperone complex. The disruption of the HSP90 complex consequently releases the 
HSF1 (heat shock factor1), which leads to an increased expression of HSP90 and 
HSP70. The current study demonstrates the changes in the proteomic profiling of the 
A549 cell lysates after they are given a 24hour treatment of the drug. The ability to 
identify the pharmacodynamic marker, HSP70 can be used to evaluate the efficacy of 
HSP90 inhibiting drugs in clinical trials. 
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Techniques like gene expression microarrays have been used to investigate the 
molecular responses to cancer drugs in tumor cells (Clarke, te Poele, & Workman, 
2004). Although valuable, analysis of gene expression at the mRNA level alone cannot 
adequately predict protein expression or functional state. In this study LC-MS/MS and 
Western Blotting analysis are used to obtain a detailed molecular signature of the action 
of 17-AAG and Radicicol. Mass Spectrometry helps us to get a proteomic picture of the 
drug treated and untreated A549 cells. The data from mass spectrometry suggests that 
there is approximately two-fold increase in the expression of inducible isoform of 
HSP90 and approximately six fold increase in the expression of the inducible isoform of 
HSP70. We validated the results with traditional Western Blotting technique. Upon 
staining with HSP90 both the 17-AAG treated and untreated A549 cell lysates, it was 
found that there is a three-fold increase in the expression of HSP70 and 1.6 fold 
increase in HSP90 in the 17AAG treated lung epithelial carcinomic cells. This is in 
agreement with the hypothesis that as the drug inhibits the binding of HSP90 to ATP, 
eventually disrupting the HSP90 complex, there should be an increase in the expression 
of HSP90. 
Western Blotting was also used to analyze A549 cells treated with Radicicol, 
Additionally in order to check effects of various concentrations of the 17AAG and 
Radicicol Western Blotting was used. Hence, Western Blotting helped to quantify the 
increase in the expression of HSP70 along with HSP90. To analyze the effects of 
Radicicol and 17AAG on primary cells we also used Mesenchymal Stem Cells apart 
from A549 cells. 
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Mass Spectrometry results show a greater increase in the expression of HS70 as 
compared to HSP90, Western Blotting results follow the same trend. After normalizing 
the HSP70 stained immunoblots with β-Actin it was found that 17AAG induces HSP70 
to a greater extent than HSP90. As shown in Figure 5.2.4.4 there is 3 fold increase in 
HSP70 expression and 1.6 fold increase in HSP90 increase on 24 hour 17-AAG 
treatment. The lower dosage of both the drugs tested did not provide a significant 
difference when samples were stained with HSP90. Both 30nM and 60nM 17-AAG 
samples show approximately 1.6 fold increase in HSP90. Interestingly 30nM 17-AAG 
treated cells did show a relatively less induction of HSP70. There was approximately 
two fold increase in expression of HSp70 with 30nM of 17-AAG treatment as compared 
to three fold increase with 60nM 17-AAG. However Western-blotting results did 
underestimate the up-regulation of HSP70 and HSP90, which can be due to saturation 
of the signal from protein bands. The fact that HSP70 gets inducted on HSP90 
inhibition the leads to questions like does the HSP70 induction attenuates the cytotoxic 
effects of HSP90 inhibitors or does HSP70 induction decreases the HSP90 inhibitor 
efficacy and hence can prove to be a big help in depleting the HSP90 client proteins.  
Using Western Blotting effect of another HSP90 inhibitor- Radicicol was studied. The 
results were similar to the HSP90 inhibitor- 17-AAG.  As shown in graph 5.2.2.3 there 
is 1.7 fold increase in the expression of HSP90 and approximately two-folds increase in 
the induction of HSP70 when A549 cells were treated with 600nM of Radicicol for 24 
hours. With 30nM Radicicol drug treatment similar increase in the expression of HSP90 
and HSP70 was observed.  As both the drugs bind at the N-terminal ATP bind site of 
HSP90, there is an increase in expression of HSP90 observed and a greater increase in 
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expression of HSP70 observed. With inhibition of HSP90, the client proteins are not 
folded properly leading to their degradation via the proteasome.  
Under stressful conditions like cancer, the transformed cells need more oncogenic client 
proteins. Theoretically we knew that these ‘client’ proteins in turn depend on HSP90 for 
their proper functioning. Maloney et al showed an increased expression of the client 
proteins upon 17-AAG and Radicicol treatments in the human ovarian cancer cell lines 
using mRNA profiling and MALDI TOF in Human Ovarian cancer cell lines.  The 
effect 17-AAG is compared to an inactive catalogue. With microarray gene expression 
profiling they show increased expression in mRNA level in genes of HSP90β and 
HSC70, both the proteins are involved in HSP90 chaperone complex. The presence of 
these heightened HSP90 complexes in tumor cells is consistent with the major role of 
HSP90 as the cancer chaperone. The proteomic analysis done following the mRNA 
analysis by Maloney et al. shows increase in expression of HSP72 and HSC70, but the 
protein levels for HSP90 α and HSP90β were shown to decrease after 24 hour of 17-
AAG treatment.  Present study shows an increased expression in the HSP90 and HSP70 
expression upon 17-AAG and Radicicol treatment using LC-MS/MS and western 
blotting. There is no inactive analogue for comparing the results of the drug treated 
samples.  
Induction of HSP70 indicates its importance as pharmacodynamic markers to study the 
pharmacology of the drugs. Interestingly, Western Blotting shows a 2-fold greater 
increase in the expression of HSP70 with Radicicol and a 3-fold increase in expression 
of HSP70 with 17-AAG. On the other hand LC-MS/MS results shows a 7 fold greater 
increase in expression of HSP70 upon 17-AAG treatments. The reason for this can be 
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the diverse role-played by HSP70 in various cellular processes including the pro-
apoptotic role. HSP70 is also involved in the apoptosis of the oncogenic client proteins 
upon HSP90 inhibition. Still the exact reason for the 7-fold greater increase in the 
expression of HSP70 in the drug treated cells as compared to the untreated cells remains 
unclear. 
Another aspect of the experiment dealt with studying the effect of HSP90 inhibiting 
drugs on primary cells. This would help us to study the effect of drugs on a wider 
variety of cells, help in the screening of drugs and study the effect of HSP90 inhibition 
on untransformed cells. In order to do so mesenchymal stem cells were used. MSC’s 
were cultured and treated with 17-AAG and Radiciol keeping the same conditions for 
culturing and drug treatment and procedure for extraction and total protein 
quantification exactly the same as used for A549 cells. There was no significant 
increase observed in the morphology and cell number of MSC’s after 24 hour of drug 
treatment. This suggests that 24 hour is not a sufficient duration of time to study the 
effect of HSP90, as 24 hours is the duration for one cell cycle of MSC. As shown in 
Figure 5.4.1.3 and 5.4.2.3 there was a 1.07 fold increase in the expression of HSP90 and 
a 1.7 fold increase in the expression of HSP70 after 24 hours of drug treatment.  This 
indicates that there is induction of HSP90 and HSP70 upon HSP90 inhibition in 
Mesenchymal Stem Cells although it is lesser as compared to HSP90 and HSp70 
induction in A549 cells. The comparison between the results from drug treated A549 
cells and Mesenchymal Stem cells indicates favorable differential effects of 17-AAG 
and Radicicol towards malignant versus non-malignant primary cells. This opens an 
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additional therapeutic window for the development of HSP90 inhibitors as drugs for 
cancer treatment. 
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Chapter 7- CONCLUSION 
 
In conclusion, the new work studies the effect HSP90 inhibition in cancerous and 
primary cells in vitro. The N-terminal HSP90 binding drug treatment of 17AAG and 
Radicicol leads to an increase in the expression of HSP90 and HSP70. As cancer 
progresses there is a higher demand of oncogenic client proteins for the functioning of 
cancer cells. These oncogenic client proteins need chaperones like HSP90 and HSP70 
for proper folding and functioning. Our results from Mass Spectrometry show 7 fold 
increase in expression in HSP70 and 2 fold increase in expression of HSP90 on 17-
AAG treatment indicating the presence of these heightened HSP90 complexes in tumor 
cells which is consistent with the major role of HSP90 as the cancer chaperone. Western 
Blotting validates this result also but underestimates the percentage increase in HSP’s. 
Upon comparing the drug effects between human lung carcinomic cell lines (A549 
cells) and Mesenchymal Stem Cells (MSC) it is found that there is induction of HSP90 
and HSP70 when there is inhibition of HSP90. 
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Chapter 8- FUTURE DIRECTION 
 
In vivo studies 
We studied the proteomic effect of HSP90 inhibition in vitro, however the in vivo effect 
must also be understood.  
Long-term effects of HSP90 inhibition 
A study can be done giving a treatment for a period of 42 or 72 hours. The previous 
work done in our labs shows the results after a 24-hour treatment of 17-AAG and 
Radicicol is given to the cancer cells. For quantification the cells can be harvested and 
Mass Spectrometry and Western Blotting can be used for studying HSP90 and HSP70 
expression. The results can be co-related with the LC-MS/MS data and a model can be 
developed to optimize the dosing and timing of the drug treatment. 
 
Proteomic profiling of MSC after HSP90 inhibition 
Proteomic technique like LC-MS/MS can be used to analyze the effects of drug 
treatment in Mesenchymal Stem cells. The results can be co-related and hence validate 
the results from Western Blotting. 
 
Combination study of HSP70 and HSP90 inhibition  
Work done in our lab shows that there is a 4-fold difference in the induction of HSP70 
upon the drug treatment as compared to HSP90. To further study the role of a greater 
increase in HSP70 expression a study can be done combining the HSp70 inhibitors and 
HSP90 inhibitors. This would help us answers questions whether the HSP70 induction 
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following HSP90 inhibition attenuates the cytotoxic effects of HSP90 inhibition or 
decrease the HSP90 inhibitor efficacy.  
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